Given that PTEN somatic mutations are not very often in human breast cancers39, the expression levels of p110δ may represent a useful straightforward marker, which can predict an effective response of those tumours expressing WT PTEN to therapy with p110δ inhibitors. This evidence concerns the gene PIK3CD and neoplasm.